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Abstract: BACKGROUND HIV drug resistance and suboptimal adherence are the main reasons for
treatment failure among HIV-infected individuals. As genotypic resistance testing is not routinely avail-
able in resource-limited settings such as Uganda, data on transmitted and acquired resistance is sparse.
METHODS This observational follow-up study assessed the virological outcomes of patients diagnosed
with virological failure or transmitted HIV drug resistance in 2015 at the adults’ out-patient clinic of
the Infectious Diseases Institute in Kampala, Uganda. Initially, 2430 patients on antiretroviral therapy
(ART) underwent virological monitoring, of which 190 had virological failure and were subsequently el-
igible for this follow-up study. Nine patients diagnosed with transmitted drug resistance were eligible.
In patients with a viral load > 1000 copies/mL genotypic resistance testing was done. RESULTS Of
190 eligible patients, 30 (15.8%) had either died or were lost to follow-up. A total of 148 (77.9%) were
included, of which 98 had had a change of ART regimen, and 50 had received adherence counselling
only. The majority was now on 2-line ART (N=130, 87.8%). The median age was 39 years (interquartile
range: 32-46) and 109 (73.6%) were female. Virological failure was diagnosed in 29 (19.6%) patients, of
which 24 (82.8%) were on 2-line ART. Relevant drug resistance was found in 25 (86.2%) cases, of which
12 (41.3%) carried dual and 7 (24.1%) triple drug resistance. CONCLUSION Two years after initial vi-
rological failure, most patients followed up by this study had a successful virological outcome. However,
a significant proportion either continued to fail or died or was lost to follow-up.
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Background: HIV drug resistance and suboptimal adherence are
the main reasons for treatment failure among HIV-infected individ-
uals. As genotypic resistance testing is not routinely available in
resource-limited settings such as Uganda, data on transmitted and
acquired resistance are sparse.
Methods: This observational follow-up study assessed the virolog-
ical outcomes of patients diagnosed with virological failure or
transmitted HIV drug resistance in 2015 at the adults’ outpatient
clinic of the Infectious Diseases Institute in Kampala, Uganda.
Initially, 2430 patients on antiretroviral therapy (ART) underwent
virological monitoring, of which 190 had virological failure and were
subsequently eligible for this follow-up study. Nine patients diagnosed
with transmitted drug resistance were eligible. In patients with a viral
load . 1000 copies/mL, genotypic resistance testing was performed.
Results: Of 190 eligible patients, 30 (15.8%) had either died or
were lost to follow-up. A total of 148 (77.9%) were included, of
which 98 had had a change of ART regimen, and 50 had received
adherence counseling only. The majority was now on second-line
ART (N = 130, 87.8%). The median age was 39 years (interquartile
range: 32–46), and 109 (73.6%) were women. Virological failure
was diagnosed in 29 (19.6%) patients, of which 24 (82.8%) were on
second-line ART. Relevant drug resistance was found in 25 (86.2%)
cases, of which 12 (41.3%) carried dual and 7 (24.1%) triple
drug resistance.
Conclusion: Two years after initial virological failure, most
patients followed up by this study had a successful virological
outcome. However, a significant proportion either continued to fail
or died or was lost to follow-up.
Key Words: HIV drug resistance, second-line treatment failure,
resource-limited setting, adherence, follow-up
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INTRODUCTION
In 2016, more than half of all HIV-infected patients
(over 25 million people) lived in sub-Saharan Africa, with an
average antiretroviral therapy (ART) coverage of 54%.1 With
the large scale-up of access to ART due to the test-and-treat
strategy, the number of patients affected by HIV drug
resistance is increasing, as recently reported by the World
Health Organization (WHO).2
According to the Ugandan Population HIV Impact
Assessment (UPHIA), 1.2 million Ugandans were living with
HIV in 2016 (prevalence 6.2% among adults), and ART
coverage was 60%.3 In the same year, the test-and-treat
approach was implemented across the country, and key
stakeholders aim to meet the UNAIDS target of 90-90-90
by the end of 2020.4,5
Rates of virological suppression on first-line ART have
previously been described to be around 85% in Uganda.6
Inappropriate switching strategies in patients failing first-line
regimens have been described in several studies and proofed
a consequent higher probability of early failure on second-line
therapy.7,8 So far, the prevalence of acquired HIV drug
resistance mutations to second-line ART remains low;
however, a mathematical model predicted an increase with
4–6 million patients in need of second-line ART by 2030 in
sub-Saharan Africa if routine viral load monitoring was made
available.9–11 As HIV drug resistance testing is still not
routinely available in low-income countries including Ugan-
da, detailed information on type and frequency of resistance-
associated mutations is sparse, especially for patients on
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second-line treatment. Moreover, at the time of this study,
patients on second-line protease inhibitor-based treatment diag-
nosed with HIV drug resistance had limited treatment options.
In Uganda, previous studies on the prevalence of
transmitted HIV drug resistance reported 4% in rural and
7% in urban areas.12,13 Currently, the WHO reports a much
higher prevalence of 18.1% of transmitted resistance to
nonnucleoside reverse transcriptase inhibitors (NNRTIs).2
In this study, we report the 2-year follow-up data on the
virological outcomes, as well as HIV drug resistance out-
comes of patients previously identified with either virological
failure on treatment or transmitted drug resistance in 2015 in
an urban Ugandan cohort.14
METHODS
Study Design and Setting
We conducted an observational, cross-sectional follow-
up study on the virological outcomes of adult patients
diagnosed with virological failure or transmitted HIV drug
resistance in 2015. This study was conducted in 2017 at the
adults’ HIV outpatient clinic of the Infectious Diseases
Institute (IDI), College of Health Sciences, Makerere Uni-
versity in Kampala, Uganda. The IDI is a center of excellence
for HIV treatment and care.15 Over 8000 HIV-infected
patients currently attend the clinic, of which the majority is
on ART. In general, patients are seen by a doctor every 3
months. Virological monitoring of patients on ART was
introduced recently. Switch options for patients diagnosed
with virological failure are discussed at a multidisciplinary
switch meeting.16 Routine resistance testing is currently
not available.
Participants and Study Size
In 2015, a first viral load was done in 2430 patients on
ART for more than 6 months, of which 190 patients had
virological failure defined as a viral load .1000 copies/mL.14
These 190 patients were eligible for inclusion into this follow-
up study. Furthermore, 9 patients diagnosed with transmitted
HIV drug resistance in 2015 were eligible for inclusion.
Data Collection
Sociodemographic information and medical history was
collected for each study participant. Data were extracted from
the IDI electronic medical record (Integrated Clinic Enterprise
Application, ICEA) or clinic files.17 On inclusion, all patients
underwent virological testing. HIV-1 RNA viral load was
determined using COBAS Ampliprep/COBAS Taqman
(Roche diagnostics, South Africa) at the Makerere
University-Johns Hopkins University (MUJHU) CORE lab-
oratory certified by the American Pathologists. Additional
venous plasma was stored at 280°C and used for retrospec-
tive genotypic HIV drug resistance testing at the Ugandan
Virus Research Institute/Medical Research Council (UVRI/
MRC) in case of persistent virological failure defined as
a viral load .1000 copies/mL. The UVRI/MRC is a WHO-
accredited laboratory for HIV-1 genotyping and HIV drug
resistance testing, which is performed using polymerase chain
reaction, gel electrophoresis and purification (QIAquick PCR
purification kit; QIAGEN, Germantown, MD), sequencing
(Big dye terminator v3.1 cycle sequencing kit; Applied
Biosystems Waltham, MA), genetic analysis (ABI 3500 and
ABI 3130 machines; Applied Biosystems), base-called se-
quences (Sequencer v5.3 and sequence alignments, BioEdit
v7.2.5 and SeaView v4.0), quality assurance (Calibrated
Population Resistance tool, Stanford and the Los Alamos
National database for the HIV Sequence Quality Analysis),
and assigning of drug resistance mutations (submission of
sequences to Stanford HIVdb Program).
Statistical Methods
We determined the proportion of patients on ART with
a viral load .1000 copies/mL in 2015. Characteristics were
compared using the Pearson x2 test or Fisher exact test for
categorical variables and the Wilcoxon rank-sum test for
continuous variables. The following characteristics were
considered in the analysis: gender, age, nadir CD4 cell count,
WHO stage, year of HIV diagnosis, ART regimen, duration
of ART, missed pills, previous side effects, ART switch
defined as any switch of drugs including single-drug sub-
stitution, and intensified adherence counseling since the start
of the study in 2015. The proportions and patterns of detected
HIV drug resistance at year 2 were described. Frequencies of
most prevalent HIV drug resistance mutations were calcu-
lated. For patients with 2 available resistance testing results
(2015 and 2017), we investigated for newly detected
mutations. Furthermore, for patients with persistent virolog-
ical failure, we described drug susceptibility to available ART
options in Uganda using Stanford HIV drug resistance
database program.20 We evaluated the drug resistance testing
results from 2015 and assessed the actions undertaken by the
medical personnel, such as treatment switch or adherence
counseling. Data management and analysis was performed
using STATA version 14.2 (College Station, TX).
The virological outcome of participants previously
identified with transmitted drug resistance was described
separately. For study participants with newly initiated ART,
drug susceptibility was retrospectively assessed comparing
Stanford HIV drug resistance database program with first
resistance results.18
Ethics
This study was reviewed and approved by the Institu-
tional Review Committee of The AIDS Support Organization
(IRC TASO, Reference Number: TASOREC/05/17-UG-
REC-009) and Uganda National Council for Science and
Technology (UNCST, Reference Number: HS33ES). All
participants gave written informed consent before
study inclusion.
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RESULTS
A total of 199 patients were eligible for study inclusion,
190 with previous virological failure, and 9 with previously
detected transmitted drug resistance mutations.
Follow-up of Patients With Virological Failure
in 2015
Of the 190 patients with virological failure in 2015, 148
were included in this follow-up study and received repeat
viral load testing, as well as HIV drug resistance testing in
case of persistent failure, as shown in Figure 1 (flow chart).
The remaining 42 patients were not included for the following
reasons: missing identification numbers (n = 2), death (n =
12), loss to follow-up (n = 18), and declined to
participate (10).
Among the 148 patients included in this follow-up
evaluation, the median age was 39 years [interquartile range
(IQR): 32–46], and 109 (73.6%) participants were women.
Most patients had WHO disease stage III (44, 29.9%) or IV
(51, 34.7%), and had been on ART for a median time of 6
years (IQR: 4–8 years). In 2015, 115 had been on first-line
ART (77.7%) and 33 (22.3%) on second-line ART. At the
follow-up evaluation 2 years later, 98 (66.2%) patients had
been switched to second-line ART amounting to 18 (12.2%)
patients on first-line ART and 130 (87.6%) patients on
second-line ART. The median time on second-line ART in
86 patients was 3.82 months (IQR 1–5); for 12 patients,
switch data were not recorded. Twenty-eight (23.5%)
patients with initial virological failure now attained a viral
load ,1000 copies/mL on ART without a change
in regimen.
During the follow-up evaluation, 29 (19.6%) patients
had a viral load .1000 copies/mL with a median viral load
of 28,387 (IQR: 8433–75,364) copies/mL. Table 1 compares
characteristics of patients with and without virological
failure. A significantly higher proportion with virological
failure was seen in patients who were on second-line ART in
2015 (14/33 versus 15/115, P value: ,0.01). Furthermore,
patients with virological failure had received a higher
number of counseling sessions, and a smaller proportion
was switched. Of all patients with virological failure, 24
(82.8%) were on second-line ART. Among these, 16
(55.2%) patients were switched between 2015 and 2017,
defined as any change in ART regimen including single-
drug substitution, and 10 from first- to second-line ART.
Among these patients, the median time on a PI-based
regimen was 4.5 months (IQR 2.5–11.25), and switch dates
were not available for 2 patients. Furthermore, Table 1
shows the distribution of NNRTI- and PI-based regimens
among our study population in 2015 and 2017. In addition,
the proportion of patients on a regimen containing tenofovir
rose from 44% (857/1932) among patients on first-line ART
in 2015, to 71% (101/148) in 2017, taking into account first-
and second-line regimens.
For 25 patients, resistance testing results from 2015
were also available. Regarding actions undertaken for these
patients, we found that 2 patients were not switched despite
available drug resistance testing and treatment options,
whereas 9 with available drug resistance testing were not
switched because of limited drug options. Furthermore, 12
patients initially identified with HIV drug resistance and
scored as susceptible to their treatment respecting their
resistance mutations had a persistent viral load
.1000 copies/mL.
HIV subtyping and resistance testing was performed in
all patients with a viral load .1000 copies/mL (n = 29).
Subtypes A (48%) and D (48%) were most common.
FIGURE 1. Enrollment flow chart.
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Relevant drug resistance mutations were found in 25
(86.2%) patients, of which 21 patients were on second-line
ART. Twelve patients (41.3%) carried dual drug resistance
mutations, and 7 (24.1%) were resistant to the 3 drug classes
currently available in Uganda, which include nucleoside/
nucleotide reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), and
protease inhibitors (PIs). As shown in Figure 2, most
common resistance mutations were M184V (18, 72%),
K103N (16, 64%), and thymidine analogue mutations
(TAM) (10, 40%). Among patients with $1 relevant drug
resistance mutation, HIV-1 susceptibility was reduced in 15
(60%) for zidovudine, in 19 (76%) for lamivudine, in 14
(56%) for tenofovir, in 22 (88%) for efavirenz and
nevirapine, and in 9 (36%) for atazanavir and lopinavir.
Resistance mutations to PIs were only seen in patients on
second-line ART.
New resistance mutations were seen in 23 patients
comparing repeated HIV drug resistance testing from 2015 to
2017. The following mutations were most likely to be
accumulated: A98G, TAMs, E44D, and M184V, as illustrated
in Figure 3.
Follow-up of Patients With Transmitted HIV
Drug Resistance Mutations
Nine patients with transmitted drug resistance were
eligible for inclusion, of which 8 were enrolled. One
patient was lost to follow-up. Table 2 summarizes their
outcomes. Six patients were initiated on ART with
tenofovir, lamivudine, and efavirenz. Of these, one was
switched to second-line ART with lopinavir/ritonavir 6
months after initiation due to treatment failure. Two
patients were still ART naive. Five of 6 patients were
started on an ART regimen to which HIV drug resistance
was initially detected for at least one substance. Neverthe-
less, 4 were virologically suppressed at a median of 18
(IQR: 17–19) months after initiation of ART. A new viral
load .1000 copies/mL at year 2 was found in one patient
out of 6 on ART with a viral load of 48,583 copies/mL.
This patient was also the only one who reported having
missed pills.
DISCUSSION
Of the 190 patients identified with virological failure
in 2015, 148 were included in this follow-up study, most
of which were found to have a successful virological
outcome after 2 years. In these cases, the successful
outcome was achieved by switching these patients to
second-line ART according to national guidelines. A
smaller proportion of patients with initial virological
failure were now suppressed on ART without a change
in regimen. These patients likely benefitted from intensive
adherence counseling.
TABLE 1. Comparing Characteristics of Patients With and Without Virological Failure
Factors
Patients With VF in 2015,
N = 148, (%)
Virological Outcomes After 2 yrs
Patients Without VF in 2017,
N = 119, (%)
Patients With VF in 2017,
N = 29, (%) P*
Female gender, N (%) 109 (73.6) 90 (75.6) 19 (65.5) 0.27
Age in years, median (IQR) 39 (32–46) 39 (32–45) 42 (34–48) 0.22
Regimen in 2015, N (%)
EFV- or NVP-based ART 115 (77.7) 100 (84.0) 15 (51.7) ,0.01
AZT/r- or LPV/r-based ART 33 (22.3) 19 (16.0) 14 (48.3)
Regimen in 2017, N (%)
EFV- or NVP-based ART 18 (12.2) 13 (10.9) 5 (17.2) 0.35
AZT/r- or LPV/r-based ART 130 (87.8) 106 (89.1) 24 (82.8)
ART switch, N (%) 107 (72.3) 91 (76.5) 16 (55.2) 0.02
WHO disease stage†, N (%)
1 10 (6.8) 7 (5.9) 3 (10.3) 0.03
2 42 (28.6) 37 (31.3) 5 (17.3)
3 44 (29.9) 39 (33.1) 5 (17.2)
4 51 (34.7) 35 (29.7) 16 (55.2)
Months since ART initiation†, median (IQR) 72 (49–107) 73 (50–105) 65 (49–115) 0.80
CD4 cell count nadir (cells/mL), median (IQR) 102 (31–182) 108 (37–184) 43 (10–172) 0.17
Number of counseling sessions received, median (IQR) 2 (1–3) 2 (1–3) 3 (2–4) ,0.01
Missed a pill within past 4 weeks, median (IQR) 27 (18.4) 19 (16.1) 8 (27.6) 0.15
Reported side effects, N (%) 18 (12.2) 11 (9.3) 7 (24.1) 0.03
VF, virological failure defined as viral load .1000 copies/mL.
*Pearson x2 P value or Fisher’s exact P values.
†Missing values for: months since ART initiation [1], WHO stage [1].
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A total of 30 (15.8%) patients with virological failure in
2015 had either died or were lost to follow-up. Furthermore,
a concerning number of patients with a viral load .1000
copies/mL were identified by this study. Most of these
patients were already on second-line ART. Furthermore, we
found a high prevalence (86.2%) of HIV drug resistance
mutations among individuals with virological failure, primar-
ily M184V, TAMs, and K103N. This finding is largely in line
with other studies from the region. However, our result on the
prevalence of TAMs differs from other studies in which
TAMs were found less frequently.19,20 Among the 23 study
participants with accumulation of HIV drug resistance
mutations, TAMs were also most frequently observed in the
2-year follow-up. This observation is likely driven by delayed
switching of a failing regimen. As TAMs might impair
second-line treatment, it is important to prevent their
accumulation and transmission. In our study, we found a small
group of patients with resistance to tenofovir (K65R/N or
K70E/G/Q), unlike the TenoRes study that reported a high
prevalence of tenofovir resistance in sub-Saharan Africa
reaching over 50% of patients with virological failure on
a tenofovir-based regimen.21
The high proportion of patients failing second-line
treatment is concerning and, regardless of the cause, puts
this group at high risk of morbidity and mortality.22 We
found a need for third-line ART (confirmed by resistance
testing) in almost half of the patients failing on second-line
ART. This finding is in agreement with other studies
showing 36% of patients failing on second-line ART at 3
years in resource-limited settings, mainly due to suboptimal
adherence rather than drug resistance.10,23,24 This suggests
that reasons for suboptimal adherence during first-line
treatment may not have been effectively addressed before
switching to second-line treatment. Considering that 14/24
patients with virological failure on second-line ART in 2017
were switched to second-line ART more than 24 months
ago, patients were on a PI-based regimen with unsuppressed
viral load for a prolonged time. Interestingly, 19 specimens
showed newly acquired NNRTI resistance mutations in
2017, although only 5 were on a NNRTI-based regimen at
FIGURE 2. Type and frequency of
most prevalent HIV drug resistance
mutations (n = 25). NNRTI, non-
nucleoside/nucleotide reverse tran-
scriptase inhibitor; NRTI, nucleoside/
nucleotide reverse transcriptase
inhibitor; PI, protease inhibitor.
FIGURE 3. Type and frequency of
most prevalent newly accumulated
mutations comparing results from
resistance testing in 2015 with re-
sults from this study (n = 23). NNRTI,
nonnucleoside/nucleotide reverse
transcriptase inhibitor; NRTI, nucle-
oside/nucleotide reverse transcrip-
tase inhibitor; PI, protease inhibitor.
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the time. We assume ongoing adherence problems in
these patients.
Furthermore, patients with multiclass drug resistance
mutations undermine that the idea of treatment as prevention
as transmission of such virus strands poses a tremendous
public health risk.25 The reason for continued virological
failure and therefore the accumulation of drug resistance
mutations over the course of time must be evaluated in detail
in these patients.
The extraordinary setting of this longitudinal follow-up
study allowed us to compare 2 subsequent resistance testing
results, which are not generally available in resource-limited
settings, and to describe its impact on the standard of care in
our clinic. We identified 2 patients who should have had
a switch of ART regimen according to their initial resistance
testing result. Furthermore, 5 patients were initiated on an
ART regimen with previously detected reduced susceptibility.
Our findings show the need to strengthen procedures on
managing patients with virological failure and HIV drug
resistance. After this study, the IDI clinic staff planned and
implemented a specialized clinic for patients with a viral load
.75 copies/mL constituted by a trained team of physicians,
nurses, and counselors. Selected patients are now referred to this
specialized team, which can see patients more frequently and
guide each patient according to their personal needs. This
promising patient management concept could reduce rates of
patients with virological failure through a very personalized
approach to care. In addition, making HIV drug resistance
testing available in a setting with professional staff in problem-
atic cases could greatly advance ART decision-making.26
Our study has some limitations. Our findings lack
generalizability, as data were collected at one site only. We
were further unable to contact 18 patients and subsequently
declared them as lost to follow-up. This is of concern, as these
patients were at high risk of developing HIV-associated
complications. Furthermore, we were unable to investigate
risk factors for continued virological failure due to small
numbers of participants.
In conclusion, ART options as recommended by WHO
treatment guidelines combined with adherence counseling are
successful in achieving suppression in the majority of HIV-
infected patients with treatment failure. Nevertheless, we
found a concerning group of patients with persistent treatment
failure on second-line ART who require special attention. We
recommend close follow-up and intensified adherence coun-
seling for patients with persistent treatment failure. And
finally, for those with extensive resistance patterns, affordable
third-line drug options need to be made accessible.
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